Related Experiment Video

Updated: May 19, 2026

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays
11:17

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays

Published on: June 13, 2019

Inhibitor scaffold for the histone lysine demethylase KDM4C (JMJD2C)

Ulrike Leurs1, Rasmus P Clausen, Jesper L Kristensen

  • 1Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, Copenhagen 2100, Denmark.

Bioorganic & Medicinal Chemistry Letters
|August 25, 2012
PubMed

Insights

Researchers identified a novel 4-hydroxypyrazole scaffold that inhibits KDM4C (JMJD2C), a histone demethylase implicated in cancers. This discovery offers a potential therapeutic strategy for cancer treatment and aids in understanding epigenetic regulation.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Epigenetics

Background:

  • The KDM4 (JMJD2) family of human histone demethylases is linked to diseases including prostate cancer, breast cancer, and X-linked mental retardation.
  • These enzymes are considered oncogenes, making their selective inhibition a potential therapeutic strategy for cancer treatment.

Purpose of the Study:

  • To screen a heterocyclic ring system library against the histone demethylase KDM4C (JMJD2C) to identify novel inhibitory scaffolds.
  • To explore the potential of identified scaffolds in developing new therapeutics and understanding KDM4C's role in epigenetic regulation.

Main Methods:

  • Screening of a heterocyclic ring system library against the KDM4C enzyme.
  • Identification and characterization of inhibitory scaffolds.

Main Results:

  • A 4-hydroxypyrazole scaffold was identified as an inhibitor of KDM4C.
  • This scaffold shows potential for further therapeutic development.

Conclusions:

  • The identified 4-hydroxypyrazole scaffold is a promising starting point for developing novel KDM4C inhibitors.
  • Further research using this scaffold can elucidate the biological roles of KDM4C in epigenetic regulation and cancer.

More Related Videos

Analysis of Histone Antibody Specificity with Peptide Microarrays09:47

Analysis of Histone Antibody Specificity with Peptide Microarrays

Published on: August 1, 2017

Assays for Validating Histone Acetyltransferase Inhibitors09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Histone Modification02:32

Histone Modification

The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
Histone Modification02:32

Histone Modification

The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
Spreading of Chromatin Modifications02:25

Spreading of Chromatin Modifications

The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer is an enzyme that can...
Histone Variants at the Centromere02:30

Histone Variants at the Centromere

Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3 variants are also...